At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 241 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads
In Brief
A Phase 4 clinical trial evaluating florbetapir F 18 for Alzheimer's Disease. Completed, enrolled 241 participants across 1 site.
Detailed Summary
This study is designed to evaluate the agreement between florbetapir F 18 scan interpretation in the clinic and by expert readers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionAug 2014
TodayJul 2026
First PostedJan 31, 2014
Enrollment StartMar 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.4 years ago
Interventions
florbetapir F 18drug
No study drug will be administered in this study - scans previously acquired in the course of clinical practice.